UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 614

Sortiert nach

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Circulation (New York, N.Y.), 2013-11, Vol.128 (19), p.2113-2120

2013

Volltextzugriff (PDF)

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

The New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509

2015

Volltextzugriff (PDF)

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.341-350

2015

Volltextzugriff (PDF)

Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9

Annual review of medicine, 2014-01, Vol.65 (1), p.417-431

2014

Volltextzugriff (PDF)

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

The Lancet (British edition), 2012-07, Vol.380 (9836), p.29-36

2012

Volltextzugriff (PDF)

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

Journal of the American College of Cardiology, 2012-06, Vol.59 (25), p.2344-2353

2012

Volltextzugriff (PDF)

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

The New England journal of medicine, 2012-03, Vol.366 (12), p.1108-1118

2012

Volltextzugriff (PDF)

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340

2015

Volltextzugriff (PDF)

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

The American journal of cardiology, 2014-09, Vol.114 (5), p.711-715

2014

Volltextzugriff (PDF)

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

The New England journal of medicine, 2014-05, Vol.370 (19), p.1809-1819

2014

Volltextzugriff (PDF)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096

2016

Volltextzugriff (PDF)

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

The Lancet (British edition), 2011-10, Vol.378 (9802), p.1547-1559

2011

Volltextzugriff (PDF)

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288

2014

Volltextzugriff (PDF)

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

The lancet. Diabetes & endocrinology, 2017-04, Vol.5 (4), p.280-290

2017

Volltextzugriff (PDF)

Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

Clinical therapeutics, 2007-07, Vol.29 (7), p.1354-1367

2007

Volltextzugriff (PDF)

MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Clinical reviews in allergy & immunology, 2018-04, Vol.54 (2), p.224-233

2018

Volltextzugriff (PDF)

Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

Current atherosclerosis reports, 2013-03, Vol.15 (3), p.310, Article 310

2013

Volltextzugriff (PDF)

Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes

Clinical therapeutics, 2015-12, Vol.37 (12), p.2751-2769

2015

Volltextzugriff (PDF)

Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades

The American journal of cardiology, 2011-07, Vol.108 (2), p.223-226

2011

Volltextzugriff (PDF)

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)

The American journal of cardiology, 2003-07, Vol.92 (2), p.152-160

2003

Volltextzugriff (PDF)

New Therapies for Reducing Low-Density Lipoprotein Cholesterol

Endocrinology and metabolism clinics of North America, 2014-12, Vol.43 (4), p.1007-1033

2014

Volltextzugriff (PDF)

Targeting LDL: Is lower better and is it safe?

Best Practice & Research Clinical Endocrinology & Metabolism, 2014-06, Vol.28 (3), p.309-324

2014

Volltextzugriff (PDF)

Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia

Journal of the American College of Cardiology, 2010-03, Vol.55 (11), p.1121-1126

2010

Volltextzugriff (PDF)

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

The American journal of cardiology, 2010-05, Vol.105 (10), p.1413-1419

2010

Volltextzugriff (PDF)

Safety and Tolerability of Dalcetrapib

The American journal of cardiology, 2009-07, Vol.104 (1), p.82-91

2009

Volltextzugriff (PDF)

1 – 25 von 614

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(573)
Mit Volltextzugriff
(543)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(614)
Japanisch
(88)
Deutsch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(408)
Life Sciences & Biomedicine
(387)
Humans
(373)
Female
(247)
Male
(216)
Middle Aged
(196)
Biological And Medical Sciences
(158)
Medical Sciences
(150)
Adult
(134)
Aged
(134)
Cardiovascular System & Cardiology
(111)
Cardiac & Cardiovascular Systems
(97)
Double-Blind Method
(85)
Cholesterol, Ldl - Blood
(84)
Cholesterol
(78)
General & Internal Medicine
(74)
Medicine, General & Internal
(72)
Risk Factors
(72)
Treatment Outcome
(67)
Anticholesteremic Agents - Therapeutic Use
(54)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes

Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three Decades

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)

New Therapies for Reducing Low-Density Lipoprotein Cholesterol

Targeting LDL: Is lower better and is it safe?

Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

Safety and Tolerability of Dalcetrapib

Suchergebnisse filtern